Cure8 research brief
A JAK inhibitor (upadacitinib) used for moderate–severe ulcerative colitis can cause neutropenia; this case report discusses how it was identified and managed, which matters for patients on the drug and clinicians monitoring safety.
Adult patients with ulcerative colitis, especially those taking or considering upadacitinib or other JAK inhibitors; clinicians managing IBD medications and safety monitoring; researchers studying JAK inhibitor safety.
The article is a subscription-access case report published in Digestive Diseases and Sciences that examines an instance of upadacitinib-associated neutropenia and discusses management considerations.
The authors reference phase 3 trials and safety/meta-analysis literature on upadacitinib and note clinical experience–based suggestions for monitoring and handling this adverse effect. The report is intended to highlight recognition and practical management rather than present new trial data.
It cites prior clinical trials, pharmacokinetic analyses, and safety meta-analyses to contextualize the case. If you take upadacitinib, routine blood monitoring and prompt communication with your care team about low white blood cell counts are the practical implications emphasized by the authors.
This is a single-case report published behind a paywall; it cites larger trials and meta-analyses for broader safety context but does not present trial-level results. Recommendations in the text are based on clinical experience and case discussion rather than new controlled data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
